
Introducing the All-seeing Eye, a groundbreaking technology that detects methylated circulating cell-free DNA released from tumors undergoing apoptosis, necrosis, and secretion into the bloodstream.
This innovative approach allows for the non-invasive monitoring of cancer progression by capturing these tumor-derived DNA fragments circulating in the blood.
By focusing on the methylation patterns specific to cancer cells, the All-seeing Eye provides a powerful and precise tool for early detection, tracking tumor dynamics, and guiding personalized treatment strategies, revolutionizing the way we approach cancer diagnostics and care.
Comments